How Low Can Gilead Sciences Stock Really Go?
Gilead Sciences navigates patent cliffs and competitive pressures in HIV and oncology, while pursuing new therapeutic areas. But as investors gauge growth prospects amid policy risks and mixed outcomes, it’s worth asking: how well can Gilead sustain innovation and market leadership?
Before judging its downturn reslience, let’s look at where Gilead Sciences stands today.
- Size: Gilead Sciences is a $179 Bil company with $29 Bil in revenue currently trading at $143.93.
- Fundamentals: Last 12 month revenue growth of 2.4% and operating margin of 39.7%.
- Liquidity: Has Debt to Equity ratio of 0.14 and Cash to Assets ratio of 0.16
- Valuation: Gilead Sciences stock is currently trading at P/E multiple of 21.0 and P/EBIT multiple of 16.5
These metrics point to a Strong operational performance, alongside Moderate valuation – making the stock Attractive. For details, see Buy or Sell GILD Stock
That brings us to the key consideration for investors looking to add GILD to their portfolio: how resilient is GILD stock if markets turn south? This is where our downturn resilience framework comes in. Suppose GILD stock falls 20-30% to $101 – can investors comfortably hold on? Turns out, the stock saw an impact slightly better than the S&P 500 index during various economic downturns, based on (a) how much the stock fell and, (b) how quickly it recovered. Below, we dive deeper into each such downturn.
- A $5.8 Billion Reason To Rethink Rivian Stock
- Should You Pay Attention To Johnson & Johnson Stock’s Momentum?
- Is Royal Caribbean Stock Poised for a Rally?
- Forget Timing the Bottom: Earn 10% While You Wait for LVS on Sale
- Wall Street Is On Sale – Time To Buy?
- What Is Happening With Analog Devices Stock?
2022 Inflation Shock
- GILD stock fell 21.3% from a high of $73.64 on 29 December 2021 to $57.92 on 10 March 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 28 October 2022
- Since then, the stock increased to a high of $155.80 on 11 February 2026 , and currently trades at $143.93
| GILD | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -21.3% | -25.4% |
| Time to Full Recovery | 232 days | 464 days |
2020 Covid Pandemic
- GILD stock fell 32.6% from a high of $84.00 on 30 April 2020 to $56.65 on 30 December 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 21 November 2022
| GILD | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -32.6% | -33.9% |
| Time to Full Recovery | 691 days | 148 days |
2018 Correction
- GILD stock fell 31.8% from a high of $88.80 on 29 January 2018 to $60.54 on 24 December 2018 vs. a peak-to-trough decline of 19.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 2 December 2022
| GILD | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -31.8% | -19.8% |
| Time to Full Recovery | 1,439 days | 120 days |
2008 Global Financial Crisis
- GILD stock fell 34.4% from a high of $28.55 on 12 August 2008 to $18.73 on 10 October 2008 vs. a peak-to-trough decline of 56.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 2 August 2012
| GILD | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -34.4% | -56.8% |
| Time to Full Recovery | 1,392 days | 1,480 days |
Feeling jittery about GILD stock? Consider portfolio approach.
The Right Way To Invest Is Through Portfolios
Stocks soar and sink – the key is staying invested. A balanced portfolio helps you ride market volatility, boosts gains and reduces single stock risk.
Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.